Efficacy and Safety of Ultra-low Dose 0.005% Estriol Vaginal Gel for the Treatment of Vulvovaginal Atrophy in Postmenopausal Women with Early Breast Cancer Treated with Nonsteroidal Aromatase Inhibitors: a Phase II, Randomized, Double-blind,...

Overview

Journal Menopause

Specialty Gynecology & Obstetrics

Date 2020 Feb 13

PMID 32049923

Citations 13

Authors

Angelica Linden Hirschberg

Pedro Sanchez-Rovira

Jesus Presa-Lorite

Miriam Campos-Delgado

Miguel Gil-Gil

Elisabet Lidbrink

Javier Suarez-Almarza

Concepcion Nieto-Magro

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the efficacy and safety of ultra-low dose 0.005% estriol vaginal gel in women with breast cancer receiving nonsteroidal aromatase inhibitors (NSAIs) and experiencing treatment-related vulvovaginal symptoms and signs.

Methods: Women with hormone receptor-positive early breast cancer receiving NSAIs were randomized to either estriol vaginal gel or placebo for 12 weeks. Vaginal maturation, vaginal pH, and total and individual scores of symptoms and signs of vulvovaginal atrophy were assessed at baseline and at weeks 3 and 12; sexual functioning was also evaluated using the Female Sexual Functioning Index (FSFI) questionnaire, as well as circulating estrogens, follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

Results: Sixty-one women with a mean age of 59 years were included: 50 received 0.005% estriol vaginal gel and 11 received placebo. Active treatment significantly improved maturation value and pH, vaginal dryness and global scores of symptoms and signs. Active treatment also increased the total FSFI score and all the FSFI domains, with the exception of pain. Small oscillations were observed in FSH and LH, which remained within the postmenopausal range. Estriol levels increased initially and normalized by week 12, and estradiol and estrone remained mostly undetectable throughout the study.

Conclusions: Ultra-low dose 0.005% estriol vaginal gel showed efficacy in improving the symptoms and signs of vulvovaginal atrophy. These results, together with minimal oscillations in hormonal levels throughout the treatment, support the use of ultra-low dose 0.005% estriol vaginal gel as a treatment option for vulvovaginal atrophy in women with breast cancer receiving NSAIs with an indication for treatment with vaginal estrogens. : Video Summary:http://links.lww.com/MENO/A531.

Citing Articles

Effect of Vaginal Laser and Topical Therapies on Vulvovaginal Atrophy Symptoms in Breast Cancer Patients: A Systematic Review and Meta-Analysis.

Loczi L, Vlesko G, Elias M, Turan C, Kajtar P, Toth R J Clin Med. 2024; 13(20).

PMID: 39458081 PMC: 11508551. DOI: 10.3390/jcm13206131.

Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-Analysis.

Ali A, Iftikhar A, Tabassum M, Imran R, Shaid M, Hashmi M J Menopausal Med. 2024; 30(2):88-103.

PMID: 39315501 PMC: 11439571. DOI: 10.6118/jmm.23037.

Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review.

Pearson A, Chen J, Dhillon H, Kiely B Breast Cancer Res Treat. 2024; 206(2):215-226.

PMID: 38780887 PMC: 11182841. DOI: 10.1007/s10549-024-07364-0.

Clinical guidelines for managing menopausal symptoms in women with (a history of) breast cancer.

Servayge J, Verduyn A, Page A, Lagaert L, Tjalma W Facts Views Vis Obgyn. 2023; 15(4):297-308.

PMID: 37963326 PMC: 10832648. DOI: 10.52054/FVVO.15.4.102.

A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors.

Hussain I, Talaulikar V Post Reprod Health. 2023; 29(4):222-231.

PMID: 37840298 PMC: 10704880. DOI: 10.1177/20533691231208473.

References

Ganz P, Rowland J, Desmond K, Meyerowitz B, Wyatt G . Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol. 1998; 16(2):501-14. DOI: 10.1200/JCO.1998.16.2.501. View

Elgart M . Cost-benefit analysis of ivermectin, permethrin and benzyl benzoate in the management of infantile and childhood scabies. Expert Opin Pharmacother. 2003; 4(9):1521-4. DOI: 10.1517/14656566.4.9.1521. View

Delgado J, Estevez J, Radicioni M, Loprete L, Moscoso Del Prado J, Nieto Magro C . Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. Climacteric. 2016; 19(2):172-80. DOI: 10.3109/13697137.2015.1098609. View

Faubion S, Larkin L, Stuenkel C, Bachmann G, Chism L, Kagan R . Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. 2018; 25(6):596-608. DOI: 10.1097/GME.0000000000001121. View

Ponzone R, Biglia N, Jacomuzzi M, Maggiorotto F, Mariani L, Sismondi P . Vaginal oestrogen therapy after breast cancer: is it safe?. Eur J Cancer. 2005; 41(17):2673-81. DOI: 10.1016/j.ejca.2005.07.015. View

Biglia N, Bounous V, Sgro L, DAlonzo M, Pecchio S, Nappi R . Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?. Clin Breast Cancer. 2015; 15(6):413-20. DOI: 10.1016/j.clbc.2015.06.005. View

Le Ray I, DellAniello S, Bonnetain F, Azoulay L, Suissa S . Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012; 135(2):603-9. DOI: 10.1007/s10549-012-2198-y. View

Sulaica E, Han T, Wang W, Bhat R, Trivedi M, Niravath P . Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2016; 157(2):203-210. DOI: 10.1007/s10549-016-3827-7. View

Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F . Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003; 45(1):29-38. DOI: 10.1016/s0378-5122(03)00087-2. View

10.

Karch F, Lasagna L . Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977; 21(3):247-54. DOI: 10.1002/cpt1977213247. View

11.

Barentsen R, van de Weijer P, Schram J . Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol. 1997; 71(1):73-80. DOI: 10.1016/s0301-2115(96)02612-7. View

12.

Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M . Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010; 26(6):404-12. DOI: 10.3109/09513591003632258. View

13.

Chen G, OLIVER R, Leung B, Lin L, Yeh J . Estrogen receptor alpha and beta expression in the vaginal walls and uterosacral ligaments of premenopausal and postmenopausal women. Fertil Steril. 1999; 71(6):1099-102. DOI: 10.1016/s0015-0282(99)00113-2. View

14.

Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M . Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas. 2012; 71(4):360-8. DOI: 10.1016/j.maturitas.2011.12.022. View

15.

. ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer. Obstet Gynecol. 2016; 127(3):e93-e96. DOI: 10.1097/AOG.0000000000001351. View

16.

Hustin J, Van den Eynde J . Cytologic evaluation of the effect of various estrogens given in postmenopause. Acta Cytol. 1977; 21(2):225-8. View

17.

Dew J, Wren B, Eden J . A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003; 6(1):45-52. View

18.

Cano A, Estevez J, Usandizaga R, Gallo J, Guinot M, Delgado J . The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause. 2012; 19(10):1130-9. DOI: 10.1097/gme.0b013e3182518e9a. View

19.

Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M . Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?. Oncologist. 2008; 13(3):222-31. DOI: 10.1634/theoncologist.2007-0234. View

20.

Melisko M, Goldman M, Rugo H . Amelioration of sexual adverse effects in the early breast cancer patient. J Cancer Surviv. 2010; 4(3):247-55. PMC: 2921487. DOI: 10.1007/s11764-010-0130-1. View